KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Net Margin (2016 - 2025)

Historic Net Margin for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to 287.29%.

  • Novavax's Net Margin fell 1437600.0% to 287.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.16%, marking a year-over-year increase of 663400.0%. This contributed to the annual value of 27.49% for FY2024, which is 279200.0% up from last year.
  • Per Novavax's latest filing, its Net Margin stood at 287.29% for Q3 2025, which was down 1437600.0% from 60.86% recorded in Q2 2025.
  • Over the past 5 years, Novavax's Net Margin peaked at 77.8% during Q1 2025, and registered a low of 380.87% during Q4 2021.
  • Over the past 5 years, Novavax's median Net Margin value was 69.94% (recorded in 2023), while the average stood at 106.92%.
  • In the last 5 years, Novavax's Net Margin surged by 7160900bps in 2021 and then plummeted by -3919600bps in 2023.
  • Quarter analysis of 5 years shows Novavax's Net Margin stood at 380.87% in 2021, then surged by 87bps to 50.99% in 2022, then fell by -20bps to 61.23% in 2023, then plummeted by -50bps to 91.76% in 2024, then tumbled by -213bps to 287.29% in 2025.
  • Its Net Margin stands at 287.29% for Q3 2025, versus 60.86% for Q2 2025 and 77.8% for Q1 2025.